January 25, 2023 – UC Asset LP (OTCQB: UCASU) management announces that the company has jump-started its plan to up-list to a major exchange, probably NASDAQ or NYSE, after it had put on hold this plan for about six months.

“Twelve months ago, we kicked off our campaign for an up-listing, and we had made solid progress toward this goal, before the dramatic change of macro-economy and stock market in general made it undesirable for us to continue the process,” explains Larry Wu, founder of UC Asset. “So we decided to freeze the plan by the end of July, 2022.”

“Despite that there are still concerns about macro-economy, as well as about the stock market, we at UC Asset have been doing well, and we have decided not to let macro-economic factors to stop us from pursuing a faster growth,” exclaims Wu.

Wu refers to the track record of the company, particularly the growth of its profit. According to its most recent annual report, the company posted net income of $0.13 per share for the year of 2021, which represented 400% growth over its $0.03 per share net income for the year of 2020. Looking forward, the management projects a $0.20 per share gross profit for the year of 2023.

Last year, the company distributed a cash dividend of $0.10 per share to its common shareholders. Management has confirmed that it will make more dividend distribution in the future.

Wu admits that the company is currently too small to justify an up-listing, as a major exchange listing will be more expensive, and will remarkably increase administration cost. Those extra cost will be difficult for a small company like UC Asset to absorb. “In order to have a meaningful uplisting, we need to increase the size of the company to at least $20 million, preferably over $30 million,” says Wu.

“Our management team has an established strategy to growth. We have identified deal pipelines with great potential, mostly of cannabis properties, for a potential portfolio expansion of $10 – $ 30 million. We have the right team to manage them. We are confident we are able to achieve the economy scale with additional capital,” Wu shares.

For this purpose, UC Asset plans to launch a SPO (secondary public offering) to raise $10 – 20 million. Wu indicates that it may also conduct a PIPE (private investment in public equity) raise prior to the SPO to raise $2 – 5 million.

“All the fund-raising will not dilute the equity of current shareholders, as our bylaw expressly prohibits the company from issuing any stocks at a price lower than the company’s net equity per share,” asserts Wu. “Particularly, we will NEVER take any investments of toxic manner, such as convertible notes of variable conversion ratios.”

“We have been very disciplined in issuing shares,” continues Wu. ” Our total issued and outstanding shares have actually decreased since our IPO, from over 5.6 million shares to less than 5.5 million shares. And last year we cancelled all our preferred units of a total number of 166,667 shares. In short, the supply of our shares is very limited, and we have adequate room to support our growth plan.”

About UC Asset LP

UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com

Disclaimer:

This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.

For More Information Contact: [email protected]

Contact Details

Larry Wu

[email protected]

Company Website

http://www.ucasset.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vancouver, British Columbia – May 18, 2021 – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW; OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, announced today that it has been added to “the Cannabis ETF” (NYSE: THCX) (“THCX“), an exchange traded fund trading on NYSE Arca.

“As the only publicly traded, pure-play company that is biosynthetically producing cannabinoids, inclusion in THCX will allow us to reach a much broader group of investors looking to capture the large, global, total addressable market Willow is targeting,” said Trevor Peters, Willow’s President & Chief Executive Officer. “As we have just commenced the commercialization stage of our first cannabinoid, cannabigerol (“CBG”), this milestone comes at the perfect time as we are transitioning into a revenue generating company.”

Listed on NYSE Arca, THCX tracks the Innovation Labs Cannabis Index, a portfolio of 33 stocks that are expected to benefit from the growth of the legal global marijuana, cannabidiol (“CBD”) and hemp industries. Willow’s inclusion in the index is part of THCX’s expansion to include various cannabis industry sub-themes, which now includes Willow’s industry leading platform manufacturing capabilities which results in ultra-pure, sustainably produced cannabinoids that are created with a fraction of the environmental footprint that traditional plant cultivation yields. Willow’s technology is intended to appeal to investors looking to participate in the next generation of cannabinoid manufacturing.

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company that develops and produces high-purity, plant derived ingredients for consumer care, food and beverage, and pharmaceutical products. Willow’s manufacturing process creates a consistent, scalable and sustainable product that benefits industry and consumers. Willow’s team has a proven track record of developing and commercializing bio-based manufacturing processes and products for both the consumer and pharmaceutical industries.

For further information, please email [email protected]; visit our website at www.willowbio.com or contact:

Trevor Peters

President and Chief Executive Officer

T: (403) 669-4848

Troy Talkkari, CFA

Vice President, Corporate Development

T: (403) 618-1117

150, 2250 Boundary Road Burnaby, BC V5M 3Z3

“High Tide’s inclusion in THCX is a significant vote of confidence in the progress we have made growing and expanding our business, particularly in the United States“, said Raj Grover, President and Chief Executive Officer of High Tide. “Today’s news provides us with an additional tool to broaden our reach and profile among U.S. investors who are attracted to High Tide’s consistent track record of delivering profitability and results for shareholders. With our pending listing on Nasdaq, we hope that more institutions and ETFs will continue to take positions in High Tide”, added Mr. Grover.

<!– Click –> <!– –><!–

$(document).ready(function(){ $.xVerifyService({ services: { email: {field: ’email’} }, submitType: ‘onChange’ });
});
–>